The People at Hydra > Management

Russell Herndon, President and Chief Executive Officer

Russell Herndon comes to Hydra with over 25 years of experience in the healthcare and biotechnology industries, with a proven track record in building successful business infrastructures, pioneering innovative corporate and regulatory processes and advancing products through development. His industry experience includes senior management positions at Genzyme Corporation and Antigenics Inc., where he led some of the companies' most strategic and important initiatives. At Antigenics, Russ served as Chief Operating Officer and President from November 2000 through December 2005. He was with Genzyme Corporation from 1989 through 2000 holding various management positions, including President of Genzyme Tissue Repair, Senior Vice President of Genzyme Tissue Repair and Vice President of regulatory affairs for Genzyme Corporation. Prior to joining Genzyme, Russ gained extensive experience in the area of quality systems, including management positions at Patton Company, Paco Research & Development and Alcon Laboratories Incorporated. Russ received a bachelor's degree in biology from Barton College and is a graduate of the Management Development Program at Harvard Business School.

 

Tom Burke, Vice President of Finance and Treasurer

Tom Burke joined Hydra in 2007. He has 15 years of experience with key strengths in the areas of strategic planning, forecasting and budgeting, equity and debt financing and internal reporting analysis. Tom spent the last 5 years heading up the finance group for Infinity Pharmaceuticals. During his tenure at Infinity, Tom lead the effort in taking the company public as well as spearheading the company's SOX compliance efforts. Prior to his tenure at Infinity, Tom was a Senior Manager at KPMG in Boston and a Manager in the Dublin, Ireland office.

 

Bert Chenard, Ph.D., Vice President, Chemistry

Bert Chenard joins Hydra with 30 years of industry experience specializing in ion channel and G-protein coupled receptor (GPCR) research. Previously, Dr. Chenard served as Sr. Vice President of Chemistry and Process Research at Neurogen Corp. In this role, he delivered a dozen small molecule development candidates including Adipiplon, a subtype-selective GABA agonist. Prior to Neurogen, Dr. Chenard was a Research Advisor at Pfizer Inc. in a career spanning over 15 years. His research efforts at Pfizer generated several development candidates including Traxoprodil, the first highly selective NR2B antagonist. Dr. Chenard began his career at DuPont's Experimental Station doing exploratory organic chemistry. Here, he discovered several specialized reagents, including TMSOK, which are of general use to synthetic chemists. Dr. Chenard received his B.A. at Central Connecticut State University and a Ph.D. from Ohio State University. He has more than 100 publications and granted U.S. patents.

 

Magdalene Moran, Ph.D., Vice President, Biology

Dr. Moran is a leading researcher and noted expert in the Transient Receptor Potential (TRP) family of ion channels. Dr. Moran joined Hydra Biosciences in 2002 as one of its first scientists. Her experience and leadership in the area of ion channel biology has led to the selection of new TRP targets to help identify novel drugs to treat pain, inflammation, pulmonary and other diseases. In her current role at Hydra Biosciences as Vice President of Biology, Dr. Moran has responsibility and oversight for the target discovery, electrophysiology and high-throughput screening functions. In the past, her group's work has uncovered a critical role for TRPA1 in neurogenic inflammation and asthma. Prior to joining Hydra Biosciences, Dr. Moran was a researcher in Dr. David Clapham's Lab at Children's Hospital in Boston where she cloned several novel ion channels including Hv1, the first voltage-gated proton channel. Dr. Moran received a B.A. in Biology from Williams College, and holds a Ph.D. in Neuroscience from Harvard University.